Share

Our COVID-19 Response Efforts

ohnson & Johnson has been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.

With our global reach comes a responsibility and unique ability to leverage our deep scientific expertise and extensive partnerships to take on this challenge. Our more than 130,000 employees around the world are mobilizing with urgency to address the critical needs of families, communities and healthcare providers around the world.

Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.

Latest announcements on Johnson & Johnson’s efforts to address the pandemic and media resources
Live Video Series
The Road to a Vaccine
"The Road to a Vaccine" is a groundbreaking eight-episode series that explores the COVID-19 crisis and the urgent global efforts to develop a vaccine candidate to help fight the pandemic.
Episode 7
What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
In Episode 7, Lisa Ling speaks with Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., about important advances being made in vaccine development. Former FDA Commissioner Mark McClellan, M.D., Ph.D., discusses what reopening could look like and global health leader Jonathan Quick, M.D., MPH, shares why he believes testing is critical to help manage this pandemic.
What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
    Episode 1
    Join host Lisa Ling as she interviews scientists and healthcare workers about how vaccines work, the impact of the COVID-19 pandemic and what’s being done globally to create a novel coronavirus vaccine.
    How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There
    How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There
    Episode 2
    Three leading scientists who have been on the frontlines of Zika, malaria and HIV give you the inside scoop on vaccine development and the process of going from lab to clinic.
    What it Takes to Create a Coronavirus Vaccine in Record Time
    What it Takes to Create a Coronavirus Vaccine in Record Time
    Episode 3
    Lisa Ling interviews National Academies member and University Professor at the University of Connecticut, Cato Laurencin, M.D., Ph.D., to learn what his new coronavirus study reveals. Plus, what’s needed to mass-produce a vaccine and what we’ve learned from other outbreaks.
    Why is COVID-19 Hitting Minority Communities So Hard?
    Why is COVID-19 Hitting Minority Communities So Hard?
    Episode 4
    This week we hear from two ER doctors about what they’ve learned from caring for COVID-19 patients. A renowned epidemiologist shares why testing is so important. A Nigerian doctor who recovered from Ebola herself talks about how fighting this outbreak is different. Plus, a leading scientist talks about how long vaccine immunity could last.
    What Doctors On The Front Lines of COVID-19 Are Now Saying About the Virus
    What Doctors On The Front Lines of COVID-19 Are Now Saying About the Virus
    Episode 5
    Two nurses—one on the front lines in the ICU, and one leading the charge to advocate for her profession—talk about what caring for patients, and each other, really means right now. An activist talks about recovering from the virus and a scientist shares the challenges of creating a vaccine for clinical. Plus, Arianna Huffington and Husseini K. Manji, MD, FRCPC, discuss the other COVID-19 crisis: how it's impacting mental health.
    How Nurses Are Battling the COVID-19 Pandemic
    How Nurses Are Battling the COVID-19 Pandemic
    Episode 6
    May 19, 2020
    Lisa Ling speaks with the Chair of the Coalition for Epidemic Preparedness Innovations, a supply chain expert and the President of Global Public Affairs at UPS about what it will take to get a vaccine to the people who need it. Plus, a young Nigerian activist on her outreach efforts.
    How the Global Community is Coming Together to Battle COVID-19
    How the Global Community is Coming Together to Battle COVID-19
    Episode 7
    In Episode 7, Lisa Ling speaks with Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., about important advances being made in vaccine development. Former FDA Commissioner Mark McClellan, M.D., Ph.D., discusses what reopening could look like and global health leader Jonathan Quick, M.D., MPH, shares why he believes testing is critical to help manage this pandemic.
    What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
    What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine

COVID-19: A Timeline

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs. J&J is mobilizing resources to find solutions for COVID-19.

December 31, 2019

China alerted the World Health Organization (WHO) to several cases of pneumonia in Wuhan. The virus is unknown.

January 7, 2020

WHO announces they have identified a new virus named 2019-nCoV, also known as Wuhan coronavirus. It is from the CoV family, which includes SARS and the common cold.

January 11, 2020

First death linked to 2019-nCoV.

January 12, 2020

J&J initiates efforts to develop a vaccine candidate against 2019-nCoV and to broadly collaborate with others to screen a library of antiviral molecules.

January 30, 2020

WHO declares the 2019-nCoV outbreak a public health emergency of international concern (PHEIC).

February 1, 2020

First death linked to 2019-nCoV was reported outside of China, in the Philippines.

February 11, 2020

COVID-19 is announced as the official name of the disease caused by novel coronavirus. The virus is named SARS-CoV-2.

February 11, 2020

J&J announces collaboration with U.S. Department of Health & Human Services to accelerate development of a potential COVID-19 vaccine.

February 18, 2020

J&J announces expanded collaboration with U.S. Department of Health & Human Services to accelerate discovery of potential COVID-19 treatments.

February 23, 2020

Europe has its first major outbreak of COVID-19, in the Lombardy region of northern Italy

February 26, 2020

The first case of COVID-19 was reported in South America, marking the spread of the disease to six of seven continents.

March 11, 2020

WHO declares the COVID-19 outbreak a pandemic.

March 27, 2020

J&J announces a $50 million commitment to support frontline health workers battling COVID-19.

March 30, 2020

J&J announces a lead vaccine candidate will move into trials and pledges to supply 1B vaccines worldwide for emergency pandemic use. BARDA and J&J commit $1B to vaccine R&D.

April 23, 2020

J&J enters into a collaboration with Emergent BioSolutions, Inc., to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

December 31, 2019

January 7, 2020

January 11, 2020

January 12, 2020

January 30, 2020

February 1, 2020

February 11, 2020

February 11, 2020

February 18, 2020

February 23, 2020

February 26, 2020

March 11, 2020

March 27, 2020

March 30, 2020

April 23, 2020

Social Media Updates

  • What makes #COVID19 more dangerous than a typical flu? Former FDA Commissioner Mark McClellan, M.D., Ph.D., shares… https://t.co/lO36wLmSB5
  • RT @IFPMA: .@IFPMA media briefing 28 May, with: •Pascal Soriot, @AstraZeneca •Emma Walmsley, @GSK •Dr. Albert Bourla, @Pfizer •Paul Stof…
  • RT @JNJGlobalHealth: Nurses witness firsthand what it will take to beat #COVID19. The #NurseHack4Health merged health workers' expertise an…

More From Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue